After the United States Supreme Court ruling in the Association for Molecular Pathology v. Myriad Genetics in June of 2013, the industry scurried. The Court ruled that naturally occurring DNA is not patent eligible even if isolated, but cDNA or “complementary DNA” is because it is not naturally occurring but rather a product of the laboratory scientist…
We are again excited to welcome thought leader Dr. Stephen Tedeschi as a guest blogger. Dr. Tedeschi, is a Partner at PatentVantage, a leading patent research and strategy firm. He is also an Adjunct Faculty member at the National Institute of Health’s Foundation for Advanced Education in the Sciences (FAES). For more on Dr. Tedeschi,…
We are excited to welcome thought leader Dr. Stephen Tedeschi as a guest blogger. Dr. Tedeschi, is a Partner at PatentVantage, a leading patent research and strategy firm. He is also an Adjunct Faculty member at the National Institute of Health’s Foundation for Advanced Education in the Sciences (FAES). For more on Dr. Tedeschi, please…
We welcome back guest blogger and thought leader Professor Chris Holman at the University of Missouri-Kansas City Law School for a new two part series. Professor Holman authors the well-known Holman’s Biotech IP Blog and is the executive editor of Biotechnology Law Report.
With the United States Supreme Court ruling in Myriad, the enforceability of certain claims in existing gene patents and the broader patentability of genetic material has been cast into a state of some disarray.
With the United States Supreme Court ruling in Myriad, the enforceability of certain claims in existing gene patents and the broader patentability of genetic material has been cast into a state of some disarray.
With the United States Supreme Court ruling in Myriad, the enforceability of certain claims in existing gene patents and the broader patentability of genetic material has been cast into a state of some disarray.
I’m going to let you in on a little secret: there’s a reason why we are the market leader in patent sequence search. It has surprisingly little to do with our user-friendly search interface, our stellar customer support, or our good looks. While (at least some of) these things certainly help, it is the content…
After 15 years in this field and writing about this many times, I’m still shocked when I see professional IP people that use BLAST for their sequence searches. BLAST is a crude and unreliable way to align sequences, and under normal circumstances it shouldn’t be used for anything patent related. There, I said it. Sequences…
Those of you who have read my previous blog post 10 Reasons Why Research Scientists Should Patent Search know that I use patents to find information about my research topics. One of the most valuable resources I had when I first started researching patents was a lengthy (and rather technical) introduction to the way they…